Novavax announced on Thursday February 10 an 80% effectiveness for its vaccine against Covid-19 in adolescents aged 12 to 17, and plans to submit this data to health authorities around the world
“in the first quarter of 2022”
.
Read alsoCould the new Novavax vaccine convince the last recalcitrants?
This two-dose vaccine was tested in clinical trials in the United States on more than 2,200 adolescents, at a time when the Delta variant was dominant.
Some participants received the vaccine, others a placebo.
Side effects were usually pain at the injection site, headache, or fatigue.
The few confirmed cases in the group of vaccinated teenagers turned out to be mild, the company also said.
"We believe Novavax's vaccine offers a different technology and option for this younger population, given its well-established protein-based technology already used in other vaccines, and the positive responses against the variants
, "
said in a press release Filip Dubovsky, chief medical officer of this American company.
Read alsoCovid-19: green light for the Novavax vaccine in France, based on classic technology
Novavax has also announced that it intends to initiate clinical trials in younger age groups in the second quarter of 2022. The company submitted an authorization request for its vaccine in adults to the Agency at the end of January. American Drug Administration (FDA).
It is already licensed for adults in Europe, including France and Britain, and has received emergency approval from the World Health Organization (WHO).
In the United States, only the Pfizer vaccine is currently authorized in children and adolescents.
